Meta-Analysis
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Dec 28, 2021; 9(6): 585-597
Published online Dec 28, 2021. doi: 10.13105/wjma.v9.i6.585
Efficacy and safety of fingolimod in stroke: A systemic review and meta-analysis
Kai Zhao, Yu Guo, Ming-Fei Yang, Qiang Zhang
Kai Zhao, Yu Guo, Graduate School, Qinghai University, Xining 810016, Qinghai Province, China
Ming-Fei Yang, Qiang Zhang, Department of Neurosurgery, Qinghai Provincial People's Hospital, Xining 810007, Qinghai Province, China
Author contributions: Zhang Q and Zhao K conceived the idea and designed the study; Zhao K and Guo Y screened the studies and extracted the data independently; Yang MF and Guo Y analysed and interpreted the data; Zhao K and Guo Y wrote the first draft of the manuscript; Zhang Q proofread the manuscript before submission; all authors reviewed the manuscript and approved the final version.
Supported by the National Key R&D Program of China, No. 2018YFC1312601; and the Project of Science and Technology Department of Qinghai Province, No. 2020-ZJ-774.
Conflict-of-interest statement: On behalf of all authors, the corresponding author states that there is no conflict of interest to disclose.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiang Zhang, MD, PhD, Chief Doctor, Surgeon, Department of Neurosurgery, Qinghai Provincial People's Hospital, No. 2 Gonghe Road, Xining 810007, Qinghai Province, China. zhangqiang691212@163.com
Received: August 18, 2021
Peer-review started: August 18, 2021
First decision: November 2, 2021
Revised: November 13, 2021
Accepted: December 24, 2021
Article in press: December 24, 2021
Published online: December 28, 2021
Core Tip

Core Tip: Brain tissue injury in stroke patients involves inflammation around the infarction lesion or hematoma, which is an important reason for disease deterioration and can result in a poor prognosis. Our systemic review and meta-analysis of recent randomized controlled trials found that fingolimod might improve neurological function in stroke patients by reducing lymphocyte infiltration in the brain effectively; however, we did not find the evidence that fingolimod could promote infarction lesion or hematoma absorption. In general, oral fingolimod (0.5 mg/d, 3 consecutive days) was safe in stroke patients except for some rare severe adverse events.